Intuitive Surgical Drops 28%: Goldman Sachs Targets $558, Says Wall Street Missed 23% Revenue Growth

For investors, the 28% meltdown in Intuitive Surgical shares is either a buying opportunity of a lifetime or a value trap — and Goldman Sachs is betting heavily on the former. While multiple bulge-bracket banks downgraded the stock after Q1 earnings, David Roman sees a clear mispricing: robust 23% revenue growth, expanding procedure volumes, and a proven playbook from past instrument lifecycle changes. With the forward P/E compressed to about 32x, the risk/reward has rarely been this compelling.

Intuitive Surgical (NASDAQ: ISRG) has seen its shares tumble 28% in 2026, triggering a series of downgrades from major Wall Street firms — until Goldman Sachs analyst David Roman issued a bold defense. The catalyst for the sell-off was the company's decision to extend the usable lifetimes of two categories of surgical instruments: increasing the reuse limit on five force-feedback tools from six to 15 procedures, and a smaller increase on older standard instruments. Investors feared these changes would erode Intuitive's lucrative razor-and-blade recurring revenue model, but Roman argues the market fundamentally misunderstands the strategy. In a note upgrading the stock with a $558 price target, Roman points out that the force-feedback extension has zero impact on revenue per procedure — it is designed to relieve supply chain constraints and accelerate hospital adoption of advanced force-sensing technology. The older instrument extension could marginally lower instruments and accessories revenue, but builds long-term customer loyalty and competitive moat.

“

The first-quarter results underscore the company's underlying strength: total revenue grew 23% year over year to $2.77 billion, and instruments and accessories alone rose 23% to $1.69 billion, despite the instrument changes being enacted.

The first-quarter results underscore the company's underlying strength: total revenue grew 23% year over year to $2.77 billion, and instruments and accessories alone rose 23% to $1.69 billion, despite the instrument changes being enacted. Earnings per share of $2.28 represented an 18.7% increase. Yet analysts at Deutsche Bank, Bank of America, JPMorgan Chase, and HSBC downgraded ISRG immediately after these otherwise robust numbers, citing the potential revenue headwind from instrument repricing. The divergence in opinion highlights a classic debate around medtech business models: short-term recurring revenue versus long-term installed base growth.

Goldman Sachs' contrarian bet is rooted in history. Roman notes that Intuitive has repeatedly extended instrument lives over its 25-year trajectory — from da Vinci S to Xi to the current X platform — and each time, temporary revenue softness was followed by a surge in procedure volumes that more than compensated. The current force-feedback tools, such as SureForm staplers and force-sensing bipolar instruments, are high-demand products whose usage growth is limited by production capacity, not demand. By tripling the number of uses, Intuitive effectively expands the supply of these tools to more surgeons without waiting for new manufacturing lines to come online. This should drive higher adoption of the force-feedback ecosystem, which commands premium pricing over conventional instruments.